Adlai Nortye wins FDA IND clearance for AN4035 ADC trial expansion to US

PUBT · 1d ago
Adlai Nortye wins FDA IND clearance for AN4035 ADC trial expansion to US
  • Adlai Nortye received U.S. FDA IND clearance for AN4035, enabling its Phase I trial to expand into the U.S.
  • First patient dosed in Australia in the global Phase I study for CEACAM5-enriched, RAS-addicted solid tumors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adlai Nortye Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080700PRIMZONEFULLFEED9822373) on September 08, 2026, and is solely responsible for the information contained therein.